FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Northey Robert Allen
 2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2015		 3. Issuer Name and Ticker or Trading Symbol
Oculus Innovative Sciences, Inc. [OCLS]
(Last)
(First)
(Middle)
C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD.		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Exec. VP of Res & Devlpment
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

PETALUMA, CA 94954		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) 10/01/2005 10/01/2015 Common Stock 1,964 $ 71.12 D  
Stock Option (Right to Buy) 07/05/2005 01/03/2016 Common Stock 714 $ 71.12 D  
Stock Option (Right to Buy) 06/15/2007 06/15/2017 Common Stock 230 $ 50.89 D  
Stock Option (Right to Buy) 06/15/2007 06/15/2017 Common Stock 4,591 $ 50.89 D  
Stock Option (Right to Buy) 12/09/2008 12/09/2018 Common Stock 14,286 $ 2.8 D  
Stock Option (Right to Buy) 02/25/2010 02/25/2020 Common Stock 12,857 $ 12.81 D  
Stock Option (Right to Buy) 05/17/2011 05/17/2021 Common Stock 15,714 $ 13.23 D  
Stock Option (Right to Buy)   (1) 09/19/2023 Common Stock 18,729 $ 2.97 D  
Stock Option (Right to Buy)   (2) 03/04/2024 Common Stock 100,702 $ 3.9 D  
Stock Option (Right to Buy)   (3) 08/21/2025 Common Stock 50,000 $ 1.16 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Northey Robert Allen
C/O OCULUS INNOVATIVE SCIENCES, INC.
1129 N. MCDOWELL BLVD.
PETALUMA, CA 94954		       Exec. VP of Res & Devlpment  

Signatures

/s/ Robert Miller as attorney-in-fact 09/02/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Options will vest 1/36th per month over a three-year vesting schedule commencing on September 19, 2013.
(2) Options will vest 1/36th per month over a three-year vesting schedule commencing on March 4, 2014.
(3) Options will only vest in whole or in part in the event the executive achieves a minimum of 80% of each of his Target Milestones in the fiscal year ending March 31, 2016 as determined by the Compensation Committee by June 30, 2016. If such executive does not achieve 80% of each of their Target Milestones, then 100% of the options will expire. If the executive achieves at least 80% of their Target Milestones by March 31, 2016, then 80% of the executive's options will vest on June 30, 2016. The vesting of the remaining 20% is in the discretion of the Compensation Committee and will vest on June 30, 2016, if at all.
 
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.